Nucleic acid- based therapeutic evaluation
Gene expression studies
This is a trial of prospective collection of serial blood samples after administration of COVID-19 vaccine in patients with cancer who are receiving active cancer treatment, planned to start therapy with 14 days of consent, or have had stem cell transplant. Cancer treatments and administration of vaccine are not controlled by the study.
This study proposes to examine the effectiveness of a Learning Collaborative’s effort that helps local community organizations address disparities in COVID-19 testing by building “Local Health Equity Action Teams” in 10 disproportionally COVID-19-affected counties.
COVID-19 morbidity and mortality has been associated with Cytokine Release Syndrome (CRS) and Acute Respiratory Distress Syndrome (ARDS). ATI-450 is an oral small molecule MAPKAPK2 (MK2) inhibitor that potently inhibits multiple inflammatory cytokines. The investigator hypothesizes that MK2 pathway blockade during active COVID-19 infection in hospitalized participants will result in improvement in respiratory-failure free survival.
A prospective testing SARS-Cov-2/COVID-19 in cancer patients with antitumor treatment (DOI: 10.1158/1557-3265.COVID-19-PO-043 Published September 2020)
Preliminary analysis of factors associated with COVID-19-related disease severity in cancer patients: University of Kansas Cancer Center experience (DOI: 10.1158/1557-3265.COVID-19-PO-082 Published September 2020)
Prospective voluntary SARS-CoV-2 virus and anti-COVID-19 antibody tests in asymptomatic medical and research staff who work in direct contact with cancer patients: A single center study (DOI: 10.1158/1557-3265.COVID-19-21-P13 Published March 2021)